COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany)

Ibrahim El-Battrawy, Ivan J Nuñez-Gil, Mohammad Abumayyaleh, Vicente Estrada, Víctor Manuel Becerra-Muñoz, Aitor Uribarri, Inmaculada Fernández-Rozas, Gisela Feltes, Ramón Arroyo-Espliguero, Daniela Trabattoni, Javier López-País, Martino Pepe, Rodolfo Romero, Alex F Castro-Mejía, Enrico Cerrato, Thamar Capel Astrua, Fabrizio D'Ascenzo, Oscar Fabregat-Andres, Jaime Signes-Costa, Francisco Marín, Danilo Buonsenso, Alfredo Bardají, María Jesús Tellez, Antonio Fernández-Ortiz, Carlos Macaya, Ibrahim Akin, Ibrahim El-Battrawy, Ivan J Nuñez-Gil, Mohammad Abumayyaleh, Vicente Estrada, Víctor Manuel Becerra-Muñoz, Aitor Uribarri, Inmaculada Fernández-Rozas, Gisela Feltes, Ramón Arroyo-Espliguero, Daniela Trabattoni, Javier López-País, Martino Pepe, Rodolfo Romero, Alex F Castro-Mejía, Enrico Cerrato, Thamar Capel Astrua, Fabrizio D'Ascenzo, Oscar Fabregat-Andres, Jaime Signes-Costa, Francisco Marín, Danilo Buonsenso, Alfredo Bardají, María Jesús Tellez, Antonio Fernández-Ortiz, Carlos Macaya, Ibrahim Akin

Abstract

Background: A systematic analysis of concomitant arterial hypertension in COVID-19 patients and the impact of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) have not been studied in a large multicentre cohort yet. We conducted a subanalysis from the international HOPE Registry (https://hopeprojectmd.com, NCT04334291) comparing COVID-19 in presence and absence of arterial hypertension.

Materials and methods: Out of 5837 COVID-19 patients, 2850 (48.8%) patients had the diagnosis arterial hypertension. 1978/2813 (70.3%) patients were already treated with ACEI or ARBs. The clinical outcome of the present subanalysis included all-cause mortality over 40 days of follow-up.

Results: Patients with arterial hypertension suffered significantly more from different complications including respiratory insufficiency (60.8% vs 39.5%), heart failure (9.9% vs 3.1%), acute kidney injury (25.3% vs 7.3%), pneumonia (90.6% vs 86%), sepsis (14.7% vs 7.5%), and bleeding events (3.6% vs 1.6%). The mortality rate was 29.6% in patients with concomitant arterial hypertension and 11.3% without arterial hypertension (P < .001). Invasive and non-invasive respiratory supports were significantly more required in presence of arterial hypertension as compared without it. In the multivariate cox regression analysis, while age≥65, benzodiazepine, antidepressant at admission, elevated LDH or creatinine, respiratory insufficiency and sepsis might be a positive independent predictors of mortality, antiviral drugs, interferon treatment, ACEI or ARBs at discharge or oral anticoagulation at discharge might be an independent negative predictor of the mortality.

Conclusions: The mortality rate and in-hospital complications might be increased in COVID-19 patients with a concomitant history of arterial hypertension. The history of ACEI or ARBs treatments does not seem to impact the outcome of these patients.

Keywords: COVID; hypertension.

Conflict of interest statement

None.

© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Kaplan‐Meier curve of survival over 40 days of follow‐up in presence and absence of arterial hypertension
FIGURE 2
FIGURE 2
Kaplan‐Meier curve of survival in patients with arterial hypertension and concomitant treatment with ACEI or ARBs as compared to arterial hypertension without ACEI or ARB treatment
FIGURE 3
FIGURE 3
The outcome and in‐hospital course of patients with continued treatment of ACEI ond ARBs vs stopped treatment is presented. Different complications including respiratory insufficiency (RI), heart failure (HF), acute kidney injury (AKI), upper respiratory tract infection (URTI), pneumonia, sepsis, O2 requirement at admission, invasive respiratory support (MV) or use of high‐flow nasal cannula (HFNC) are compared (*P < .05, **P < .001)

References

    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
    1. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019‐nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689‐697.
    1. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS‐CoV‐2). Science. 2020;368(6490):489‐493.
    1. Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID‐19 epidemic in China. Science. 2020;368(6491):638‐642.
    1. Pan A, Liu L, Wang C, et al. Association of Public Health Interventions with the epidemiology of the COVID‐19 outbreak in Wuhan, China. JAMA. 2020;323(19):1915‐1923.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062.
    1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS‐CoV‐2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574‐1581.
    1. Aronson JK, Ferner RE. Drugs and the renin‐angiotensin system in covid‐19. BMJ. 2020;369:m1313.
    1. Fosbol EL, Butt JH, Ostergaard L, et al. Association of angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker use with COVID‐19 diagnosis and mortality. JAMA. 2020;324(2):168‐177.
    1. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin‐angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID‐19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825‐830.
    1. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin‐angiotensin‐aldosterone system blockers and the risk of Covid‐19. N Engl J Med. 2020;382(25):2431‐2440.
    1. Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID‐19). JAMA Cardiol. 2020;5(9):1020‐1026.
    1. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35‐53.
    1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID‐19 infection? Lancet Respir Med. 2020;8(4):e21.
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475‐481.
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720.
    1. Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID‐19. Nat Biotechnol. 2020;39(6):705‐716.
    1. Li W, Moore MJ, Vasilieva N, et al. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450‐454.
    1. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury. Nat Med. 2005;11(8):875‐879.
    1. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019‐nCoV. Biochem Biophys Res Commun. 2020;525(1):135‐140.
    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin‐converting enzyme 2 (ACE2) as a SARS‐CoV‐2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586‐590.
    1. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin‐converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized With COVID‐19. Circ Res. 2020;126(12):1671‐1681.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa